VentriPoint Diagnostics Ltd.

VentriPoint Diagnostics Ltd.

December 08, 2009 08:00 ET

VentriPoint Announces Acceptance of Clinical Validation Study for Publication

SEATTLE, WASHINGTON--(Marketwire - Dec. 8, 2009) - VentriPoint Diagnostics Ltd. ("VentriPoint" or the "Corporation") (TSX VENTURE:VPT) is pleased to announce that the manuscript entitled, "Accuracy of Knowledge Based Reconstruction (KBR) for Measurement of Right Ventricular Volume and Function in Patients with Tetralogy of Fallot" has been accepted for publication in the American Journal of Cardiology. The study will be published in the journal's April, 2010 issue.

This study demonstrated the accuracy and reproducibility of the KBR method which enables physicians to monitor their patients' hearts from ultrasound or magnetic resonance images. The results of the study were presented at the Scientific Sessions of the American Heart Association in November, 2008 by the lead author, Dr. Florence Sheehan, a cardiologist and professor at the University of Washington. She led a multinational team of investigators in collecting and analyzing patient data for the study.

The KBR method was successfully applied for patients with the most common type of congenital heart disease (CHD) causing a "blue baby" at birth. Studies are in progress at VentriPoint to validate KBR for the other types of CHD. The investigative team has enlarged to now include sites in Canada, the UK, the Netherlands, and Switzerland in addition to the U.S., indicating the intense clinical need everywhere for VentriPoint's service.

"The acceptance of this manuscript by such an esteemed authority as the American Journal of Cardiology represents a validation of our efforts to introduce a much needed tool for monitoring right ventricular volume and function from 2D Ultrasounds images," stated Joe Ashley, President & CEO of the Corporation. "We continue to pursue the European and U.S. regulatory authority and the requisite capital to commercialize our exceptionally accurate system to health professionals as a tool for their diagnosis and treatment of cardiovascular disease. Rapid and accurate right ventricle measurements is essential for patient assessment."

There are greater than 1 million American adults and 800,000 children with CHD, according to the American Heart Association and the Adult Congenital Heart Association. With 36,000 CHD births every year, the number of CHD patients requiring serial RV monitoring is rising due to their longer survival as a result of extremely successful diagnostic and treatment strategies developed and employed over the past 40 years. VentriPoint also plans to extend its service to patients with other types of lung and heart diseases, bringing the total estimated market for the VentriPoint Medical System to exceed $5 Billion worldwide.

About VentriPoint Diagnostics Ltd.
VentriPoint creates diagnostic tools to monitor patients with heart disease – the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Medical System ("VMS") generates critical heart measurements in a rapid, accurate and inexpensive manner not currently available. Health Canada has granted licensed approval for the VMS breakthrough diagnostic tool which is based upon technology received by VentriPoint through its exclusive technology license with the University of Washington. The VMS, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease and pulmonary hypertension.

To receive press release, please email and mention VentriPoint in the Subject line.

FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address VentriPoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • VentriPoint Diagnostics
    Ed Garth
    Chief Financial Officer
    (206) 283-0221, ext. 402
    (206) 283-2309 (FAX)
    CHF Investor Relations
    Christopher Haldane
    Account Manager
    (416) 868-1079 ext.237
    (416) 868-6198 (FAX)